Combined together, these variations in n-9/n-7 isomers of C18:1-containing GPs suggested that there must be some other factors that influence the C=C location isomeric ratio, and the universality of drugs targeting SCD1 treatment should be well considered since different cancer cell subtypes respond differently even within the same cancer type. The gene discussed is SCD; the disease is cancer.